The Plan subscribes to the goals and pillars of the WHO Global Technical Strategy against Malaria 2016-2030 (GTS), while presenting key elements to address the specific challenges of the Region.
Le document fournit des messages éducatifs et des conseils pratiques pour prévenir et gérer la diarrhée, en particulier chez les enfants. Il met l'accent sur les pratiques d'hygiène telles que le lavage des mains adéquat, l'utilisation de latrines et la manipulation sûre des aliments. Il soul...igne également l'importance de l'allaitement maternel, d'une alimentation équilibrée, de la vaccination et de l'utilisation de solutions de réhydratation orale (SRO) et de zinc pour traiter la déshydratation causée par la diarrhée. Développé en collaboration avec les programmes de Save the Children en République démocratique du Congo, le matériel intègre l'éducation à la santé dans les écoles et les communautés, en encourageant les enfants à agir comme agents de changement pour promouvoir les pratiques d'hygiène et de santé.
more
At the end of 2023, WHO convened our first-ever annual WHO Stakeholder Review Conference for Prevention and Response to Sexual Misconduct. Aimed at joint learning and frank discussion on challenges faced in the achieving zero tolerance for all forms of sexual misconduct by aid workers, the Conferenc...e brought together Member States, Civil Society Organizations, United Nations Agencies and Programmes, academia and media joined by WHO personnel. A set of recommendations to support all agencies are documented in the Conference Report. In addition, WHO’s Director-General hosted a social engagement segment on the evening of Day 1 to further underscore the centrality of a victim and survivor-centred approach, to celebrate progress however small, and to reaffirm commitment and renew energy for the journey ahead. The Conference took place on 30 November and 1 December 2023 in Geneva, Switzerland
more
THIS LEAFLET AIMS AT GUIDING YOU THROUGH THE VERY FIRST DAYS OF AN OUTBREAK
This is an update (third edition) of the BACPR Standards & Core Components and represents current evidence-based best practice and a pragmatic overview of the structure and function of Cardiovascular Prevention and Rehabilitation Programmes (CPRPs) in the UK. The previously described seven standards... have now been reduced to six but without sacrificing any of the key elements and with a greater emphasis placed on measurable clinical outcomes, audit and certification. Similarly, the second edition provided an overview of seven core components felt to be essential for the delivery of quality prevention and rehabilitation, and this too has been reduced to six. The interplay between cardio-protective therapies and medical risk factors is almost impossible to disentangle for the vast majority of patients and even if specific drug therapies are deployed exclusively for risk factor modulation, the indirect effect will also be cardio-protective. Thus, these have been combined into a single core component – medical risk management.
more
A resposta a um surto de cólera focaliza geralmente os aspectos médicos que são importantes para reduzir a mortalidade. Contudo, há necessidade de uma resposta mais abrangente para limitar a propagação da doença. Como a resposta a surtos é geralmente dirigida por profi ssionais médicos, pod...e haver tendência para negligenciar outros aspectos, tais como problemas ambientais ou de comunicação.
more
The COTS Cholera Outbreak Training and Shigellosis Program Pocket Card provides essential guidelines for health promotion workers to prevent and manage cholera and shigellosis outbreaks. It emphasizes proper sanitation, hygiene practices, safe water handling, and food safety as the primary methods f...or disease control. Key recommendations include handwashing, disinfecting water with chlorine, using latrines, and ensuring safe food preparation. The document also outlines hospital policies, waste disposal procedures, and safety measures for healthcare workers dealing with diarrheal diseases. Additionally, it provides dehydration assessment guidelines, treatment protocols using Oral Rehydration Solution (ORS) and IV fluids, and appropriate antibiotic treatments for both cholera and shigellosis. The goal is to equip healthcare workers with quick-reference tools to effectively contain outbreaks and prevent further transmission.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
A Global Inventory of Alternative Medical Waste Treatment Technologies